The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/II study of the A2AR antagonist NIR178 (PBF-509), an oral immunotherapy, in patients (pts) with advanced NSCLC.
 
Alberto Chiappori
Honoraria - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech; Merck; Novartis; Pfizer; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; genentech; Novartis
Speakers' Bureau - Boehringer Ingelheim; Celgene; Genentech; Merck; Novartis; Pfizer; Takeda
Research Funding - Bristol-Myers Squibb; Novartis
 
Charles C. Williams
Speakers' Bureau - Celgene
 
Ben C. Creelan
Consulting or Advisory Role - Abbvie; Celgene
Speakers' Bureau - ARIAD; AstraZeneca; Bristol-Myers Squibb; Genentech
Research Funding - Boehringer Ingelheim; Lion Biotechnologies
 
Tawee Tanvetyanon
No Relationships to Disclose
 
Jhanelle Elaine Gray
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Celgene; Genentech/Roche; Janssen; Lilly
Speakers' Bureau - Genentech
Research Funding - Array BioPharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Epic Sciences (Inst); Genentech/Roche (Inst); Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Genentech/Roche; Janssen Oncology
 
Eric B. Haura
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen Oncology
Research Funding - Boehringer Ingelheim; FORMA Therapeutics; Ignyta; Janssen; Lilly
Patents, Royalties, Other Intellectual Property - Patent pending on PLA technology related to kinase inhibitor sensitivity biomarkers
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche
 
Ram Thapa
No Relationships to Disclose
 
Dung-Tsa Chen
Research Funding - Abbvie (Inst)
 
Amer A. Beg
Research Funding - Celgene
 
Theresa A. Boyle
Other Relationship - Bristol-Myers Squibb
 
Jennifer Bendiske
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Erick Morris
Employment - Merck (I); Novartis
Stock and Other Ownership Interests - Merck (I); Novartis
Patents, Royalties, Other Intellectual Property - Novartis
 
Aiyang Tao
Employment - Novartis
 
Felipe K. Hurtado
Employment - Novartis
 
Luigi Manenti
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Patents, Royalties, Other Intellectual Property - Novartis
Travel, Accommodations, Expenses - Novartis
 
Julio Castro
Employment - Palobiofarma
Leadership - Palobiofarma
Stock and Other Ownership Interests - Palobiofarma
Honoraria - Palobiofarma
Research Funding - Palobiofarma
Patents, Royalties, Other Intellectual Property - Palobiofarma
Travel, Accommodations, Expenses - Palobiofarma
 
Scott Joseph Antonia
Stock and Other Ownership Interests - Cellular Biomedicine Group
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck; Novartis
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck